Company intelligence / Profile preview
DURECT Corporation
Cupertino, California, United Statesprnewswire.com ↗
- Ownership
- Public · DRRX
- Development stage
- Phase 3
01
Overview
Larsucosterol demonstrated positive results in the Phase IIb AHFIRM trial for severe alcohol-associated hepatitis, published in NEJM Evidence January 2025. The FDA granted Breakthrough Therapy Designation based on these data. A registrational Phase III trial design has been finalized incorporating recent feedback and data.
- Therapeutic areas
- GastroenterologyPsychiatryMetabolic DisordersNephrologyOncologyNeurology
- Modalities
- Small molecules (notably epigenetic modulators)Long-acting injectables (drug delivery platforms such as SABER®, CLOUD™)Biodegradable implants and microparticulates (historically)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Innocoll Pharmaceuticals (POSIMIR US commercialization)Orient Pharma (Methydur)Charles River Laboratories (ALZET product line marketing agreement until divestiture)past collaborations with pharma partners on drug delivery technologies.
04
Financials
- Market cap
- $59.3M
- Total revenue
- $447K
- Enterprise value
- $54.6M
Beyond the preview
Go deeper on DURECT Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DURECT Corporation.